DeBacker J R, McMillan G P, Martchenke N, Lacey C M, Stuehm H R, Hungerford M E, Konrad-Martin D
VA RR&D National Center for Rehabilitative Auditory Research, VA Portland Health Care System, 3710 SW US Veterans Hospital Road (NCRAR - P5), Portland, OR, 97239, USA.
Oregon Health and Science University, Portland, OR, USA.
J Cancer Surviv. 2023 Feb;17(1):82-100. doi: 10.1007/s11764-022-01315-8. Epub 2023 Feb 2.
A cornerstone of treatment for many cancers is the administration of platinum-based chemotherapies and/or ionizing radiation, which can be ototoxic. An accurate ototoxicity risk assessment would be useful for counseling, treatment planning, and survivorship follow-up in patients with cancer.
This systematic review evaluated the literature on predictive models for estimating a patient's risk for chemotherapy-related auditory injury to accelerate development of computational approaches for the clinical management of ototoxicity in cancer patients. Of the 1195 articles identified in a PubMed search from 2010 forward, 15 studies met inclusion for the review.
All but 1 study used an abstraction of the audiogram as a modeled outcome; however, specific outcome measures varied. Consistently used predictors were age, baseline hearing, cumulative cisplatin dose, and radiation dose to the cochlea. Just 5 studies were judged to have an overall low risk of bias. Future studies should attempt to minimize bias by following statistical best practices including not selecting multivariate predictors based on univariate analysis, validation in independent cohorts, and clearly reporting the management of missing and censored data. Future modeling efforts should adopt a transdisciplinary approach to define a unified set of clinical, treatment, and/or genetic risk factors. Creating a flexible model that uses a common set of predictors to forecast the full post-treatment audiogram may accelerate work in this area. Such a model could be adapted for use in counseling, treatment planning, and follow-up by audiologists and oncologists and could be incorporated into ototoxicity genetic association studies as well as clinical trials investigating otoprotective agents.
Improvements in the ability to model post-treatment hearing loss can help to improve patient quality of life following cancer care. The improvements advocated for in this review should allow for the acceleration of advancements in modeling the auditory impact of these treatments to support treatment planning and patient counseling during and after care.
许多癌症治疗的基石是铂类化疗和/或电离辐射,而这些治疗可能具有耳毒性。准确的耳毒性风险评估对于癌症患者的咨询、治疗计划制定以及生存随访会有所帮助。
本系统评价评估了关于预测模型的文献,这些模型用于估计患者发生化疗相关听觉损伤的风险,以加速癌症患者耳毒性临床管理计算方法的开发。在2010年起的PubMed搜索中识别出的1195篇文章里,有15项研究符合该评价的纳入标准。
除1项研究外,所有研究均将听力图摘要用作建模结果;然而,具体的结果测量方法各不相同。一致使用的预测因素包括年龄、基线听力、顺铂累积剂量以及耳蜗的辐射剂量。仅有5项研究被判定总体偏倚风险较低。未来的研究应遵循统计最佳实践以尽量减少偏倚,包括不基于单变量分析选择多变量预测因素、在独立队列中进行验证以及清晰报告缺失数据和删失数据的处理方法。未来的建模工作应采用跨学科方法来定义一套统一的临床、治疗和/或遗传风险因素。创建一个使用一组通用预测因素来预测整个治疗后听力图的灵活模型,可能会加速该领域的工作。这样的模型可被听力学家和肿瘤学家用于咨询、治疗计划制定和随访,并且可纳入耳毒性基因关联研究以及研究耳保护剂的临床试验中。
改善对治疗后听力损失进行建模的能力有助于提高癌症治疗后患者的生活质量。本评价中所倡导的改进措施应能加速在对这些治疗的听觉影响进行建模方面取得进展,以支持治疗期间和治疗后的治疗计划制定及患者咨询。